Group One Trading
ALLO icon

Group One Trading’s Allogene Therapeutics ALLO Stock Holding History

Group One Trading’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.95K Buy
1,900
+900
+90% +$1.98K ﹤0.01% 6821
2026
Q1 		$2.44K Buy
1,000
+800
+400% +$1.6K ﹤0.01% 6990
2025
Q4 		$274 Hold
200
– – ﹤0.01% 7860
2025
Q3 		$248 Sell
200
-26,400
-99% -$31.5K ﹤0.01% 8203
2025
Q2 		$30.1K Buy
26,600
+20,900
+367% +$27.8K ﹤0.01% 5981
2025
Q1 		$8.32K Buy
5,700
+5,500
+2,750% +$10.4K ﹤0.01% 6381
2024
Q4 		$426 Sell
200
-100
-33% -$247 ﹤0.01% 7015
2024
Q3 		$840 Sell
300
-16,500
-98% -$44K ﹤0.01% 6317
2024
Q2 		$39.1K Buy
16,800
+5,100
+44% +$15K ﹤0.01% 4711
2024
Q1 		$52.3K Sell
11,700
-72,700
-86% -$303K ﹤0.01% 4678
2023
Q4 		$271K Sell
84,400
-5,200
-6% -$14.7K ﹤0.01% 3585
2023
Q3 		$284K Buy
89,600
+23,800
+36% +$104K ﹤0.01% 3485
2023
Q2 		$327K Buy
65,800
+25,800
+65% +$140K ﹤0.01% 3455
2023
Q1 		$198K Buy
40,000
+39,600
+9,900% +$254K ﹤0.01% 3692
2022
Q4 		$2.52K Sell
400
-3,200
-89% -$29.6K ﹤0.01% 6578
2022
Q3 		$39K Buy
3,600
+3,100
+620% +$42.1K ﹤0.01% 5585
2022
Q2 		$6K Sell
500
-800
-62% -$7.1K ﹤0.01% 6978
2022
Q1 		$12K Sell
1,300
-49,600
-97% -$517K ﹤0.01% 7076
2021
Q4 		$759K Buy
50,900
+50,800
+50,800% +$896K ﹤0.01% 3638
2021
Q3 		$3K Sell
100
-2,500
-96% -$59.4K ﹤0.01% 7847
2021
Q2 		$68K Buy
2,600
+2,400
+1,200% +$68.4K ﹤0.01% 6314
2021
Q1 		$7K Sell
200
-300
-60% -$10.1K ﹤0.01% 7143
2020
Q4 		$13K Sell
500
-100
-17% -$3.26K ﹤0.01% 5687
2020
Q3 		$23K Sell
600
-1,200
-67% -$45.2K ﹤0.01% 5057
2020
Q2 		$77K Buy
+1,800
New +$65.1K ﹤0.01% 4096
2020
Q1 		– Sell
-8,100
Closed -$210K – 5188
2019
Q4 		$210K Buy
8,100
+7,900
+3,950% +$218K ﹤0.01% 3134
2019
Q3 		$5K Sell
200
-800
-80% -$22.8K ﹤0.01% 4753
2019
Q2 		$27K Buy
1,000
+900
+900% +$25.1K ﹤0.01% 4052
2019
Q1 		$3K Buy
+100
New +$2.9K ﹤0.01% 4509

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Group One Trading's ALLO Position: Q2 2026 in Review

Group One Trading increased its Allogene Therapeutics (ALLO) stake by 100% in Q2 2026, buying an estimated $8.84K and bringing the position to 8,039 shares worth $16.7K. The position accounts for ﹤0.01% of the portfolio, ranked #6122.

Group One Trading first reported a position in ALLO in Q1 2019 and has held it in 22 quarters since. The position peaked at $697K in Q1 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Group One Trading held 8,039 shares of Allogene Therapeutics worth $16.7K as of Q2 2026.
  • Group One Trading bought 4,025 Allogene Therapeutics shares in Q2 2026, an estimated $8.84K.
  • Allogene Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #6122 holding.
  • Group One Trading first reported a position in Allogene Therapeutics in Q1 2019 and has held it in 22 quarters since.
  • Group One Trading's Allogene Therapeutics position peaked at $697K in Q1 2021.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.